Quoin Pharmaceuticals (QNRX) AI Stock Analysis

• Market Cap: $6.63M
• Dividend Yield: N/A
• Average Volume (3M): 629.04K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.16
• Revenue Growth: N/A
• EPS Growth: -228.89%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.71
• Shares Outstanding: 838,977
• 10 Day Avg. Volume: 1,633,105
• 30 Day Avg. Volume: 629,040
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.01
• Enterprise Value/Market Cap: -1.15
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.55
• 1Y Price Target: $70.00
• Price Target Upside: 497.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $11.50 ▼(-1.88% Downside)

The score is held back primarily by weak financial performance (no revenue, ongoing losses, and heavy cash burn with reduced balance-sheet flexibility). Offsetting factors include constructive corporate developments (orphan designation and significant financing runway) and a technically improved longer-term trend, while valuation remains constrained by negative earnings.

Positive Factors

Awareness Campaign Success

The success of the NETHERTON NOW campaign enhances Quoin's visibility and credibility in addressing rare diseases, potentially aiding future product acceptance and partnerships.

Leadership Strength

The appointment of an experienced CFO strengthens Quoin's financial leadership, which is crucial for navigating commercialization and financial challenges.

Product Pipeline Progress

Progress in clinical studies for QRX003 indicates potential for future revenue generation and market entry, critical for long-term growth.

Negative Factors

Financial Instability

The lack of revenue and reliance on external financing highlight financial instability, posing risks to operational sustainability and growth.

Negative Cash Flow

Persistent negative cash flow and dependence on external funding raise concerns about Quoin's ability to sustain operations without new revenue streams.

Lack of Profitability

The absence of revenue and profitability underscores significant challenges in achieving financial stability, impacting long-term viability.

Quoin Pharmaceuticals Business Overview & Revenue Model

Company Description

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

How the Company Makes Money

Quoin Pharmaceuticals generates revenue through the development and commercialization of its pharmaceutical products. The company's revenue model primarily involves the sale of its approved drugs and potential licensing agreements with other pharmaceutical firms. As Quoin continues to advance its product candidates through clinical trials, successful approvals and subsequent market launches are anticipated to be key revenue drivers. Additionally, the company may enter into strategic partnerships or collaborations that could provide milestone payments and royalties, further contributing to its earnings. Significant factors influencing its revenue include the successful development of its pipeline products, obtaining regulatory approvals, and the establishment of distribution networks for commercializing its therapies globally.

Quoin Pharmaceuticals Financial Statement Overview

Summary

Quoin Pharmaceuticals is facing significant financial challenges with zero revenue, consistent losses, and a heavy reliance on external financing. The company's financial position is precarious, with no clear path to profitability or positive cash flow from operations.

Income Statement

Quoin Pharmaceuticals has consistently reported zero revenue over the years, leading to negative net income, indicating a lack of operational profitability. The absence of revenue growth or positive margins highlights significant challenges in achieving financial stability.

Balance Sheet

The company's balance sheet shows a positive equity position as of the latest report, primarily due to strong financing activities. However, the lack of revenue generation and historical negative equity and high liabilities present risks to financial stability and growth.

Cash Flow

Quoin Pharmaceuticals struggles with negative operating and free cash flow, indicating difficulties in generating cash from operations. The reliance on financing to support cash flow needs raises concerns about long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-14.00M	-9.43M	-9.27M	-8.56M	-20.27M	-1.57M
Net Income	-13.77M	-8.96M	-8.69M	-9.38M	-21.46M	-2.10M
Balance Sheet
Total Assets	6.42M	15.71M	12.17M	14.46M	9.36M	1.38M
Cash, Cash Equivalents and Short-Term Investments	5.41M	14.06M	10.69M	12.85M	7.48M	323.83K
Total Debt	0.00	0.00	0.00	0.00	0.00	1.21M
Total Liabilities	7.64M	6.50M	6.51M	7.05M	8.70M	7.99M
Stockholders Equity	-1.21M	9.20M	5.66M	7.41M	657.03K	-6.61M
Cash Flow
Free Cash Flow	-10.74M	-7.86M	-7.86M	-8.73M	-6.35M	-1.46M
Operating Cash Flow	-10.74M	-7.86M	-7.86M	-8.48M	-5.72M	-1.34M
Investing Cash Flow	3.81M	-1.89M	2.19M	-10.15M	-625.00K	-125.00K
Financing Cash Flow	5.64M	10.97M	5.22M	14.01M	13.50M	1.79M

Quoin Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNRX, the sentiment is Negative. The current price of 11.72 is below the 20-day moving average (MA) of 13.34, below the 50-day MA of 14.16, and above the 200-day MA of 9.84, indicating a neutral trend. The MACD of -0.69 indicates Positive momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 4.21 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNRX.

Quoin Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QNRX	52 Neutral	$6.63M	-0.02	-655.85%	―	―	-228.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JAGX	45 Neutral	$2.86M	-0.02	-370.95%	―	12.45%	-544.23%
GLMD	44 Neutral	$4.51M	-0.22	-46.34%	―	―	70.71%
CLDI	44 Neutral	$8.03M	-0.12	―	―	―	87.42%
ADIL	41 Neutral	$6.20M	-0.25	-155.01%	―	―	78.52%

Quoin Pharmaceuticals Corporate Events

Quoin Pharmaceuticals Approves New Stock Option Agreements

On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors approved new award agreements for stock options under the company’s 2025 Equity Incentive Plan. These agreements outline the terms for granting equity awards to directors and executive officers, including various payment methods for exercising options and conditions for awards upon termination of employment. This move aims to enhance the company’s ability to attract and retain top talent, potentially impacting its competitive position in the pharmaceutical industry.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery

On November 11, 2025, Quoin Pharmaceuticals announced the successful achievement of target loading concentrations for its two topical rapamycin delivery technologies. A 4% concentration was achieved in their topical formulation and a 5% concentration in a dermal patch system. The company plans to manufacture clinical trial batches this quarter and begin clinical testing in the first half of 2026, targeting conditions like Microcystic Lymphatic Malformations and Venous Malformations, for which there are currently no FDA-approved treatments.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.

Quoin Pharmaceuticals Receives FDA Orphan Drug Designation

On October 21, 2025, Quoin Pharmaceuticals announced that the U.S. FDA granted Orphan Drug Designation to its lead product candidate, QRX003, for treating Netherton Syndrome. This designation, which follows a similar recognition by the European Medicines Agency in May 2025, provides benefits like tax credits and market exclusivity. QRX003 is being evaluated in late-stage clinical trials, with enrollment expected to complete in early 2026, and a new drug application submission planned for later that year. The designation could facilitate QRX003’s approval pathway in the U.S., potentially making it the first approved treatment for Netherton Syndrome.

The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.